Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Response in the SAPHO Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01688219
Recruitment Status : Completed
First Posted : September 19, 2012
Last Update Posted : September 19, 2012
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The aetiology of SAPHO syndrome seems to involve genetic, infectious and immunological components. The investigators examined innate and adaptative immune responses in SAPHO syndrome as compared with psoriatic arthritis and rheumatoid arthritis.

Condition or disease
SAPHO Syndrome

Layout table for study information
Study Type : Observational
Actual Enrollment : 39 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Immune Mechanisms During SAPHO Syndrome and Treatment by Etarnecept
Study Start Date : November 2005
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. IL-8 production by PMN [ Time Frame: 24 h ]

Secondary Outcome Measures :
  1. TNFalpha production by PMN [ Time Frame: 24 h ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
SAPHO syndrome patients
Criteria

Inclusion Criteria:

  • Clinical diagnosis of SAPHO syndrome
  • Must have bone lesions

Exclusion Criteria:

  • Infliximab treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01688219


Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Study Director: Gilles Hayem, PhD Assitance Publique-Hopitaux Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01688219     History of Changes
Other Study ID Numbers: 45896566645469
First Posted: September 19, 2012    Key Record Dates
Last Update Posted: September 19, 2012
Last Verified: October 2007

Keywords provided by Assistance Publique - Hôpitaux de Paris:
SAPHO syndrome
Innate immunity
TNF alpha
Polymorphonuclear neutrophils
Propionibacterium acnes
Interleukin-8

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Acquired Hyperostosis Syndrome
Disease
Pathologic Processes
Osteochondrodysplasias
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases